Aclaris Initiates Phase 1b Trial of ATI-052 for Asthma
Aclaris Therapeutics has initiated a placebo-controlled Phase 1b proof-of-concept trial of ATI-052, the Company's potential best-in-class investigational bispecific anti-TSLP/IL-4Ralpha antibody, in asthma. This announcement follows the recent initiation of the Company's Phase 1b POC trial of ATI-052 in atopic dermatitis. Planning is ongoing for a Phase 2b program encompassing asthma and atopic dermatitis as potential first indications. The Company expects to initiate this program in the second half of 2026. The randomized, double-blind, placebo-controlled Phase 1b POC trial will evaluate the safety, tolerability, and efficacy of ATI-052 compared to placebo in approximately 16 patients with asthma on GINA steps 2-4 treatment prior to screening. Endpoints that will be assessed include safety and tolerability parameters; pharmacokinetic parameters; respiratory pharmacodynamic biomarker assessments including FeNO; blood PD biomarker assessments including blood eosinophil count and endogenous cytokines/chemokines and inflammation markers in plasma/serum; and efficacy measures including FEV1. Top line results from this trial and the ongoing Phase 1b POC trial in AD are expected in the second half of 2026.
Trade with 70% Backtested Accuracy
Analyst Views on ACRS
About ACRS
About the author
Aclaris Q4 Earnings Miss Expectations with Significant Revenue Decline
- Disappointing Earnings: Aclaris Therapeutics reported a Q4 GAAP EPS of -$0.16, missing expectations by $0.02, indicating ongoing pressure on profitability that may affect investor confidence.
- Significant Revenue Decline: The company generated $1.3 million in revenue, an 85.9% year-over-year drop, falling short of the expected $0.77 million, reflecting weak market demand and sales challenges that could strain future cash flow.
- Decreased Cash Reserves: As of December 31, 2025, Aclaris had cash, cash equivalents, and marketable securities totaling $151.4 million, down from $203.9 million in 2024, highlighting pressures on operational and R&D expenditures.
- Clinical Trial Progress: Despite poor financial results, Aclaris reported positive interim results from the ATI-052 Phase 1a trial, potentially laying the groundwork for future therapeutic advantages and demonstrating the company's R&D potential.
Aclaris ATI-2138 Shows Superior Efficacy in Hair Loss Treatment
- Preclinical Results: Aclaris Therapeutics' ATI-2138 demonstrated rapid and near-complete hair regrowth in a murine model, achieving 87% regrowth at week 4 compared to Pfizer's Litfulo at 48%, indicating a significant therapeutic advantage in treating autoimmune alopecia.
- Future Trial Plans: Aclaris is set to initiate a Phase 2b trial for ATI-2138 in the first half of 2026, exploring its potential for additional alopecia indications, reflecting the company's confidence in the drug's market prospects.
- Strong Stock Performance: ACRS shares are trading at $3.88, 22.6% above the 20-day simple moving average and have increased by 58.16% over the past year, showcasing robust short-term and medium-term momentum that suggests investor optimism about the company's future.
- Analyst Ratings: The stock carries a 'Buy' rating with an average price target of $10.73, while HC Wainwright & Co. maintains a target of $16, indicating strong market recognition of Aclaris' growth potential.
Aclaris Therapeutics Added to Nasdaq Biotechnology Index Effective December 19, 2025
- Index Inclusion: Aclaris Therapeutics has been added to the Nasdaq Biotechnology Index effective December 19, 2025, marking a significant recognition in the biopharmaceutical sector that enhances its market image and investor confidence.
- Market Standards: The Nasdaq Biotechnology Index aims to track the performance of securities classified as biotechnology or pharmaceutical, and Aclaris's inclusion indicates it meets various eligibility criteria, including minimum market capitalization and average daily trading volume, thereby strengthening its competitive position in the industry.
- Annual Evaluation: The index is evaluated annually in December using a modified capitalization-weighted methodology, and Aclaris's addition may attract more investor attention, potentially improving its stock liquidity and market performance.
- R&D Potential: As a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases, Aclaris's inclusion not only elevates its industry standing but may also bring additional funding support for its R&D pipeline, aiding in the development of new products to meet patient needs.
Aclaris Therapeutics Added to Nasdaq Biotechnology Index
- Inclusion in Index: Aclaris Therapeutics (ACRS) has been added to the Nasdaq Biotechnology Index.
- Announcement Timing: The announcement regarding the inclusion was made late Friday.
Aclaris Therapeutics Added to Nasdaq Biotechnology Index Effective December 19, 2025
- Index Inclusion: Aclaris Therapeutics was added to the Nasdaq Biotechnology Index at the close of trading on December 19, 2025, marking a significant recognition in the biopharmaceutical sector that enhances its market image and investor confidence.
- Market Standards: The Nasdaq Biotechnology Index requires companies to meet minimum market capitalization and average daily trading volume standards, and Aclaris's inclusion reflects its stability and growth potential in the biopharmaceutical industry.
- R&D Strength: Aclaris focuses on developing novel product candidates for immuno-inflammatory diseases, boasting a multi-stage product pipeline that underscores its ongoing commitment to addressing patient needs.
- Investor Attention: Inclusion in the index may attract more institutional investors, potentially driving up the company's stock price and strengthening its competitive position in the biopharmaceutical market.
Reasons to Consider Aclaris Therapeutics (ACRS) as a Strong Momentum Stock: Is It Time to Buy?
Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation that they will continue to rise. The Zacks Momentum Style Score helps identify stocks with strong momentum characteristics.
Aclaris Therapeutics Performance: Aclaris Therapeutics (ACRS) has a Momentum Style Score of B and a Zacks Rank of #2 (Buy), with shares increasing 19.64% over the past quarter and 66.12% over the past year, outperforming the S&P 500.
Volume and Estimate Revisions: ACRS has an average 20-day trading volume of 1,004,293 shares, indicating bullish momentum. Additionally, recent earnings estimate revisions have been positive, contributing to its favorable consensus estimate.
Investment Recommendations: The article suggests Aclaris Therapeutics as a promising stock pick for investors looking for momentum opportunities, alongside other stocks identified by Zacks Investment Research that are expected to perform well in the near term.
Aclaris Q4 Earnings Miss Expectations with Significant Revenue Decline
- Disappointing Earnings: Aclaris Therapeutics reported a Q4 GAAP EPS of -$0.16, missing expectations by $0.02, indicating ongoing pressure on profitability that may affect investor confidence.
- Significant Revenue Decline: The company generated $1.3 million in revenue, an 85.9% year-over-year drop, falling short of the expected $0.77 million, reflecting weak market demand and sales challenges that could strain future cash flow.
- Decreased Cash Reserves: As of December 31, 2025, Aclaris had cash, cash equivalents, and marketable securities totaling $151.4 million, down from $203.9 million in 2024, highlighting pressures on operational and R&D expenditures.
- Clinical Trial Progress: Despite poor financial results, Aclaris reported positive interim results from the ATI-052 Phase 1a trial, potentially laying the groundwork for future therapeutic advantages and demonstrating the company's R&D potential.
Aclaris ATI-2138 Shows Superior Efficacy in Hair Loss Treatment
- Preclinical Results: Aclaris Therapeutics' ATI-2138 demonstrated rapid and near-complete hair regrowth in a murine model, achieving 87% regrowth at week 4 compared to Pfizer's Litfulo at 48%, indicating a significant therapeutic advantage in treating autoimmune alopecia.
- Future Trial Plans: Aclaris is set to initiate a Phase 2b trial for ATI-2138 in the first half of 2026, exploring its potential for additional alopecia indications, reflecting the company's confidence in the drug's market prospects.
- Strong Stock Performance: ACRS shares are trading at $3.88, 22.6% above the 20-day simple moving average and have increased by 58.16% over the past year, showcasing robust short-term and medium-term momentum that suggests investor optimism about the company's future.
- Analyst Ratings: The stock carries a 'Buy' rating with an average price target of $10.73, while HC Wainwright & Co. maintains a target of $16, indicating strong market recognition of Aclaris' growth potential.
Aclaris Therapeutics Added to Nasdaq Biotechnology Index Effective December 19, 2025
- Index Inclusion: Aclaris Therapeutics has been added to the Nasdaq Biotechnology Index effective December 19, 2025, marking a significant recognition in the biopharmaceutical sector that enhances its market image and investor confidence.
- Market Standards: The Nasdaq Biotechnology Index aims to track the performance of securities classified as biotechnology or pharmaceutical, and Aclaris's inclusion indicates it meets various eligibility criteria, including minimum market capitalization and average daily trading volume, thereby strengthening its competitive position in the industry.
- Annual Evaluation: The index is evaluated annually in December using a modified capitalization-weighted methodology, and Aclaris's addition may attract more investor attention, potentially improving its stock liquidity and market performance.
- R&D Potential: As a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases, Aclaris's inclusion not only elevates its industry standing but may also bring additional funding support for its R&D pipeline, aiding in the development of new products to meet patient needs.
Aclaris Therapeutics Added to Nasdaq Biotechnology Index
- Inclusion in Index: Aclaris Therapeutics (ACRS) has been added to the Nasdaq Biotechnology Index.
- Announcement Timing: The announcement regarding the inclusion was made late Friday.
Aclaris Therapeutics Added to Nasdaq Biotechnology Index Effective December 19, 2025
- Index Inclusion: Aclaris Therapeutics was added to the Nasdaq Biotechnology Index at the close of trading on December 19, 2025, marking a significant recognition in the biopharmaceutical sector that enhances its market image and investor confidence.
- Market Standards: The Nasdaq Biotechnology Index requires companies to meet minimum market capitalization and average daily trading volume standards, and Aclaris's inclusion reflects its stability and growth potential in the biopharmaceutical industry.
- R&D Strength: Aclaris focuses on developing novel product candidates for immuno-inflammatory diseases, boasting a multi-stage product pipeline that underscores its ongoing commitment to addressing patient needs.
- Investor Attention: Inclusion in the index may attract more institutional investors, potentially driving up the company's stock price and strengthening its competitive position in the biopharmaceutical market.
Reasons to Consider Aclaris Therapeutics (ACRS) as a Strong Momentum Stock: Is It Time to Buy?
Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation that they will continue to rise. The Zacks Momentum Style Score helps identify stocks with strong momentum characteristics.
Aclaris Therapeutics Performance: Aclaris Therapeutics (ACRS) has a Momentum Style Score of B and a Zacks Rank of #2 (Buy), with shares increasing 19.64% over the past quarter and 66.12% over the past year, outperforming the S&P 500.
Volume and Estimate Revisions: ACRS has an average 20-day trading volume of 1,004,293 shares, indicating bullish momentum. Additionally, recent earnings estimate revisions have been positive, contributing to its favorable consensus estimate.
Investment Recommendations: The article suggests Aclaris Therapeutics as a promising stock pick for investors looking for momentum opportunities, alongside other stocks identified by Zacks Investment Research that are expected to perform well in the near term.
